Publications

Authors:

Spini, Andrea; Pellegrini, Giorgia; Ingrasciotta, Ylenia; L'Abbate, Luca; Bellitto, Chiara; Carollo, Massimo; Leoni, Olivia; Zanforlini, Martina; Ancona, Domenica; Stella, Paolo; Cavazzana, Anna; Scapin, Angela; Lopes, Sara; Belleudi, Valeria; Ledda, Stefano; Carta, Paolo; Rossi, Paola; Ejlli, Lucian; Sapigni, Ester; Puccini, Aurora; Spila Alegiani, Stefania; Massari, Marco; Guarneri, Claudio; Gisondi, Paolo; Trifirò, Gianluca

Title:

Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network

Year:

2024

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

No

Name of journal:

EXPERT OPINION ON BIOLOGICAL THERAPY

ISSN of journal:

1471-2598

N° Volume:

24

Number or Folder:

5

:

Ashley Publications Limited:Unitec House, Third Floor, 2 Albert Place, Finchley Central, London N3 1QB United Kingdom:011 44 208 3433883, EMAIL: jdrake@ashley-pub.com, INTERNET: http://www.ashley-pub.com, Fax: 011 44 208 3432313

Page numbers:

399-409

Keyword:

Biologics; biosimilars; psoriasis; psoriatic arthritis; switch; switch-back

Short description of contents:

Background: Switch patterns among different biologics and from originators to biosimilars (and vice versa) can be complex in patients with psoriasis (PsO) and psoriatic arthritis (PsA). Objective: The aim of this study was to describe switching patterns of biological drugs in PsO/PsA patients and to explore predictors of multiple switches and switch-back. Research design and methods: A large-scale retrospective cohort study was conducted using the Italian VALORE database. Bio-naïve users treated for PsO/PsA during 2010-2022 were included. Time to switch/swap and predictors of multiple switches and switch-back were analyzed. Results: Thirty-thousand seven hundred bio-naïve users were included. At 3 and 5 years of follow-up, patients with at least one switch/swap were 37.1% and 47.8%, respectively. The median time to first switch/swap was significantly shorter (p< 0.001) for TNF-α inhibitors (2,068 days) than anti-IL (2,780 days). At 1 year of follow-up patients starting with IL-23 switched/swapped biological therapy less frequently than those with anti-IL-12/23 and anti-IL-17 (4.9% vs. 8.7% and 9.4%, respectively). Patients starting with anti-IL-12/23 reported a significantly lower risk of multiple switches and switch-back (0.74, 95% CI, 0.67-0.83; 0.58, 95% CI, 0.44-0.77, respectively) than those with TNF-α inhibitors. Conclusions: Patients with PsO/PsA starting with TNF-α inhibitors switch/swap more rapidly and frequently than those with anti-IL, which are also associated with a reduced risk of multiple switches during follow-up.

Note:

Epub 2024 May 21

Product ID:

139854

Handle IRIS:

11562/1127126

Last Modified:

June 26, 2024

Bibliographic citation:

Spini, Andrea; Pellegrini, Giorgia; Ingrasciotta, Ylenia; L'Abbate, Luca; Bellitto, Chiara; Carollo, Massimo; Leoni, Olivia; Zanforlini, Martina; Ancona, Domenica; Stella, Paolo; Cavazzana, Anna; Scapin, Angela; Lopes, Sara; Belleudi, Valeria; Ledda, Stefano; Carta, Paolo; Rossi, Paola; Ejlli, Lucian; Sapigni, Ester; Puccini, Aurora; Spila Alegiani, Stefania; Massari, Marco; Guarneri, Claudio; Gisondi, Paolo; Trifirò, Gianluca, Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network «EXPERT OPINION ON BIOLOGICAL THERAPY» , vol. 24 , n. 5 , 2024 , pp. 399-409

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo